Bou Khalil R, Khoury E, Koussa S. Linking multiple pathogenic pathways in Alzheimer’s disease. World J Psychiatr 2016; 6(2): 208-214 [PMID: 27354962 DOI: 10.5498/wjp.v6.i2.208]
Corresponding Author of This Article
Rami Bou Khalil, MD, Department of Psychiatry, Hotel Dieu de France Hospital, Saint Joseph University, A. Naccache Boulevard Street, Achrafieh, PO Box 166830, Beirut, Lebanon. ramiboukhalil@hotmail.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatr. Jun 22, 2016; 6(2): 208-214 Published online Jun 22, 2016. doi: 10.5498/wjp.v6.i2.208
Linking multiple pathogenic pathways in Alzheimer’s disease
Rami Bou Khalil, Elie Khoury, Salam Koussa
Rami Bou Khalil, Elie Khoury, Department of Psychiatry, Hotel Dieu de France Hospital, Saint Joseph University, PO Box 166830, Beirut, Lebanon
Salam Koussa, Department of Neurology, Hotel Dieu de France Hospital, Saint Joseph University, PO Box 166830, Beirut, Lebanon
Author contributions: Bou Khalil R conceived the manuscript’s idea, initiated the research on the subject and prepared a first draft for the minir-review; Khoury E completed the research and contributed to the final version of the manuscript; Koussa S contributed to the elaboration of the research idea and process; all authors have read and approved the final version of this manuscript.
Conflict-of-interest statement: None declared for all authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rami Bou Khalil, MD, Department of Psychiatry, Hotel Dieu de France Hospital, Saint Joseph University, A. Naccache Boulevard Street, Achrafieh, PO Box 166830, Beirut, Lebanon. ramiboukhalil@hotmail.com
Telephone: +961-70-946430
Received: March 1, 2016 Peer-review started: March 1, 2016 First decision: March 22, 2016 Revised: April 24, 2016 Accepted: May 10, 2016 Article in press: May 11, 2016 Published online: June 22, 2016 Processing time: 110 Days and 19.2 Hours
Core Tip
Core tip: Patients with Alzheimer’s disease (AD) have not benefited from any disease-modifying drug until now. Multiple etiologic pathways have been explored and suggest promising solutions in the future. The iron chelator deferoxamine is one potential therapeutic solution around which future studies are being directed. Another potential therapeutic solution is related to thrombin inhibitors. In this minireview, a common pathophysiological pathway is suggested for the pathogenesis of AD that is initiated by the presence of vascular risk factors inducing brain tissue hypoxia and endothelial cell activation. In predisposed individuals, this can lead to thrombin activation and iron decompartmentalization. The resulting oxidative stress will eventually lead to neuronal and glial cell death.
